Modern CNS Drug Discovery : Reinventing the Treatment of Psychiatric and Neurological Disorders /
This textbook provides a comprehensive overview of the currently used concepts, approaches and technologies in the discovery and development of new treatments for the full spectrum of disorders of the central nervous system. It guides the reader through all essential steps, from finding an innovativ...
| Corporate Author: | |
|---|---|
| Other Authors: | |
| Format: | eBook |
| Language: | English |
| Published: |
Cham :
Springer International Publishing : Imprint: Springer,
2021.
|
| Edition: | 1st ed. 2021. |
| Subjects: | |
| Online Access: | Connect to the full text of this electronic book |
Table of Contents:
- PART I - Introduction
- Innovator, Entrepreneur, Leader: The Tripartite Drug Discovery Neuroscientist
- PART II - Innovation in the Discovery of Novel Therapeutic Approaches
- Drug Discovery in CNS: Finding a Target for What?
- Neurogenomics with Application to Schizophrenia and Other Major Neuropsychiatric Diseases with Complex Heredity
- Epigenetics in Drug Discovery: Achievements and Challenges
- Conventional Behavioral Models and Readouts in Drug Discovery: The Importance of Improving Translation
- Safety and Drug Metabolism: Toward NCE and First in Human
- The Various Forms of Non-invasive Brain Stimulation and Their Clinical Relevance
- Is Non-invasive Brain Stimulation the Low-Hanging Fruit?
- PART III - Translational Medicine and Technology
- Electrophysiology: From Molecule to Cognition, from Animal to Human
- MRI in CNS Drug Development
- Positron Emission Tomography in Drug Development
- Application of Cognitive Test Outcomes for Clinical Drug Development
- Exciting Research in the Field of Sexual Psychopharmacology: Treating Patients with Inside Information
- A Paradigm Shift from DSM-5 to Research Domain Criteria: Application to Translational CNS Drug Development
- PART IV - Clinical Development and Regulatory Approval
- The Special Challenges of Developing CNS Drugs
- Phase 1 Clinical Trials in Psychopharmacology
- Early Development of Erenumab for Migraine Prophylaxis
- Microdosing Psychedelics as a Promising New Pharmacotherapeutic
- Partnering with the FDA.